文献速递神经肿瘤

一例错配修复缺陷侵袭性垂体腺瘤患者对免疫检查点抑制剂治疗达完全缓解:病例报告

Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
PubMed 文献 · Neurosurgery · 2022-05-13

57岁男性侵袭性垂体腺瘤患者,术后16个月复发,替莫唑胺3周期后进展,二代测序检出MLH1与TP53体细胞突变,接受伊匹木单抗/纳武利尤单抗免疫治疗后术后34个月MRI未见残留肿瘤负荷。作者认为该病例显示免疫治疗在侵袭性垂体腺瘤中的效用,复发完全消退且生存优于预期寿命。

要点

  • 侵袭性垂体腺瘤对标准治疗难治,替莫唑胺是欧洲内分泌学会指南推荐唯一有 documented 疗效的化疗药。
  • 本例为稀疏颗粒型促肾上腺皮质激素细胞腺瘤伴恶变,免疫组化示MLH1与PMS2表达缺失。
  • 替莫唑胺3周期后MRI示明显进展,伊匹木单抗/纳武利尤单抗治疗后术后34个月MRI无残留肿瘤负荷。

核心结论

  • 侵袭性垂体腺瘤频繁复发且中位预期生存期短,本例免疫治疗后复发性侵袭性垂体腺瘤完全消退且生存优于预期寿命,作者认为显示免疫治疗的效用。

研究设计与样本

  • 单例病例报告:57岁男性,表现为视力下降和双颞侧偏盲,MRI示鞍区肿块疑为垂体大腺瘤伴垂体柄移位和视神经受压。

主要发现

  • 患者接受立体定向内镜下经蝶窦入路肿瘤切除,术后MRI示全切除,病理为稀疏颗粒型促肾上腺皮质激素细胞腺瘤伴恶变,免疫组化示肿瘤细胞MLH1与PMS2表达缺失。
  • 因Ki67指数升高和p53阳性推荐质子治疗,放疗前无影像学残留肿瘤证据;术后16个月 surveillance MRI 示复发后开始替莫唑胺治疗,但3周期后MRI示明显进展。
  • 二代测序(MSK-IMPACT平台)检出MLH1 Y548lfs*9与TP53 R337C体细胞突变,启动伊匹木单抗/纳武利尤单抗免疫治疗,术后34个月MRI示无残留肿瘤负荷。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND IMPORTANCE: Aggressive pituitary adenomas (APAs) are pituitary tumors that are refractory to standard treatments and carry a poor prognosis. Current treatment guidelines are not standardized but combine surgical resection, radiation therapy, and chemotherapy. Temozolomide is the only chemotherapeutic agent with documented effectiveness and is recommended for APA in European Society of Endocrinology clinical guidelines. CLINICAL PRESENTATION: A 57-year-old man presented with visual deterioration and bitemporal hemianopsia. MRI of the brain demonstrated a sellar mass suspected to be pituitary macroadenoma with displacement of the stalk and optic nerve impingement. The patient underwent stereotactic endoscopic transsphenoidal resection of the mass. Postoperative MRI demonstrated gross total resection. Pathology revealed a sparsely granulated corticotroph adenoma with malignant transformation. Immunohistochemistry showed loss of expression of MLH1 and PMS2 in the tumor cells. Proton therapy was recommended given an elevated Ki67 index and p53 positivity. Before radiotherapy, there was no radiographic evidence of residual tumor. Temozolomide therapy was initiated after surveillance MRI showed recurrence at 16 months postoperatively. However, MRI demonstrated marked progression after 3 cycles. Next-generation sequencing using the MSK-IMPACT platform identified somatic mutations in MLH1 Y548lfs*9 and TP53 R337C . Immunotherapy with ipilimumab/nivolumab was initiated, and MRI demonstrated no residual tumor burden 34 months postoperatively. CONCLUSION: APA is a tumor with frequent recurrence and a short median expected length of survival. Here, we demonstrate the utility of immunotherapy in a single case report of APA, with complete resolution of recurrent APA and improved survival compared with life expectancy.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Shah S, Manzoor S, Rothman Y, et al. Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report. Neurosurgery. 2022. PMID: 35544035. doi:10.1227/neu.0000000000002024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。